Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$0.29 - $0.7 $8,777 - $21,186
-30,266 Reduced 64.62%
16,571 $7,000
Q4 2023

Feb 09, 2024

BUY
$0.26 - $0.47 $11,863 - $21,444
45,627 Added 3770.83%
46,837 $21,000
Q3 2023

Nov 09, 2023

SELL
$0.23 - $0.5 $356 - $774
-1,548 Reduced 56.13%
1,210 $0
Q2 2023

Aug 11, 2023

SELL
$0.46 - $0.89 $7,292 - $14,109
-15,853 Reduced 85.18%
2,758 $1,000
Q1 2023

May 12, 2023

BUY
$0.66 - $1.4 $12,025 - $25,509
18,221 Added 4672.05%
18,611 $12,000
Q4 2022

Feb 08, 2023

BUY
$0.79 - $9.19 $308 - $3,584
390 New
390 $0
Q2 2022

Aug 10, 2022

BUY
$0.51 - $2.42 $6,258 - $29,695
12,271 Added 271.06%
16,798 $10,000
Q1 2022

May 16, 2022

SELL
$2.45 - $5.04 $17,676 - $36,363
-7,215 Reduced 61.45%
4,527 $11,000
Q4 2021

Feb 14, 2022

BUY
$4.5 - $11.91 $52,839 - $139,847
11,742 New
11,742 $56,000
Q3 2021

Nov 15, 2021

SELL
$8.52 - $24.77 $71,440 - $207,696
-8,385 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$11.62 - $44.5 $97,433 - $373,132
8,385 New
8,385 $97,000

Others Institutions Holding NRXP

About NRX Pharmaceuticals, Inc.


  • Ticker NRXP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,641,296
  • Market Cap $111M
  • Description
  • NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-10...
More about NRXP
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.